Development of a humanized HLA-A2.1/DP4 transgenic mouse model and the use of this model to map HLA-DP4-restricted epitopes of HBV envelope protein

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Ru, Zhitao ^a,b   Xiao, Wenjun ^a   Pajot, Anthony ^b   Kou, Zhihua ^a   Sun, Shihui ^a   Maillere, Bernard ^c   Zhao, Guangyu ^a   Ojcius, David M ^d   Lone, Yu chun ^b   Zhou, Yusen ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b INSERM U1014   (France)

^c SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; HEPATITIS B SURFACE ANTIGEN; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; BIOLOGICAL MARKER; HLA DP ANTIGEN; HLA DPW4 ANTIGEN; HLA-DPW4 ANTIGEN; MONOCLONAL ANTIBODY; VIRUS VACCINE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS BREEDING; EPITOPE MAPPING; HELPER CELL; HEPATITIS B VIRUS; HETEROZYGOTE; HLA SYSTEM; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN DETERMINATION; TRANSGENIC MOUSE; ANIMAL; GENETICS; HOMOZYGOTE; IMMUNOLOGY; METABOLISM; METHODOLOGY;

ANIMALIA; HEPATITIS B VIRUS; MUS; MUS MUSCULUS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPE MAPPING; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HLA-A2 ANTIGEN; HLA-DP BETA-CHAINS; HOMOZYGOTE; HUMANS; IMMUNITY, HUMORAL; MICE; MICE, TRANSGENIC; PHENOTYPE; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 84863264783     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032247     Document Type: Article

References (46)

1. Healey GD, Elvin SJ, Morton M, Williamson ED, (2005) Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei Challenge and bacterial clearance postinfection. Infect Immun 73: 5945-5951.
2. Viret C, Janeway CAJ, (1999) MHC and T cell development. Rev Immunogenet 1: 91-104.
3. Sprent J, Gao EK, Webb SR, (1990) T cell reactivity to MHC molecules: Immunity vs. tolerance. Science 248: 1357-1363.
4. Botten J, Whitton JL, Barrowman P, Sidney J, Whitmire JK, et al. (2010) A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans. J Virol 84 (19): 9947-56.
5. Ribeiro SP, Rosa DS, Fonseca SG, Mairena EC, Postol E, et al. (2010) A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules. PLoS One 5 (6): e11072.
6. Zhou WY, Shi Y, Wu C, Zhang WJ, Mao XH, et al. (2009) Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model. Vaccine 27: 5013-5019.
7. Stern JN, Illes Z, Reddy J, Keskin DB, Fridkis-Hareli M, et al. (2005) Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 102: 1620-1625.
8. Jin X, Newman MJ, De-Rosa S, Cooper C, Thomas E, et al. (2009) A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4 T cells in a Phase I clinical trial in HIV-uninfected adults. Vaccine 27: 7080-7086.
9. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, et al. (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187: 265-270.
10. Pascolo S, (2005) HLA class I transgenic mice: development, utilisation and improvement. Expert Opin Biol Ther 5 (7): 919-38.
11. Taneja V, David CS, (1998) HLA transgenic mice as humanized mouse models of disease and immunity. J Clin Invest 101 (5): 921-926.
12. Pajot A, Michel ML, Ojcius DM, Lemonnier FA, Lone YC, et al. (2004) A mouse model of human adaptive immune functions: HLA-A2.1-/ HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol 34: 3060-3069.
13. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR, (2011) Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acid Research 39: D913-D919.
14. Castelli FA, Buhot C, Sanson A, Zarour H, Pouvelle-Moratille S, et al. (2002) HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol 169: 6928-6934.
15. Geng L, Imanishi T, Tokunaga K, Zhu D, Mizuki N, et al. (1995) Determination of HLA class II alleles by genotyping in a Manchu population in the northern part of China and its relationship with Han and Japanese populations. Tissue Antigens 46: 111-116.
16. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, et al. (2009) A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 41: 591-595.
17. Guo X, Zhang Y, Li J, Ma J, Wei Z, et al. (2004) Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the han Chinese population. Hepatology 40: 318-326.
18. Baschal EE, Aly TA, Babu SR, Fernando MS, Yu L, et al. (2007) HLA-DPB1* 0402 protects against type 1A diabetes autoimmunity in the highest risk DR3-DQB1*0201/DR4-DQB1*0302 DAISY population. Diabetes 56: 2405-2409.
19. Odum N, Saida T, Ohta M, Svejgaard A, (1989) HLA-DP antigens and HTLV-1 antibody status among Japanese with multiple sclerosis: evidence for an increased frequency of HLA-DPw4. J Immunogenet 16 (6): 467-73.
20. Celis E, Karr RW, (1989) Presentation of an immunodominant T-cell epitope of hepatitis B surface antigen by the HLA-DPw4 molecule. J Virol 63: 747-752.
21. De Waal L, Yüksel S, Brandenburg AH, Langedijk JPM, Sintnicolaas K, et al. (2004) Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein. J Virol 78: 1775-1781.
22. Tang J, Olive M, Champagne K, et al. (2004) Adenovirus hexon T-cell epitope is recognized by most adults and is restricted by HLA DP4, the most common class II allele. Gene Ther 22: 1.
23. De Graaf PMA, Heidema J, Poelen MC, Van Dijk MEA, Lukens MV, et al. (2004) HLA-DP4 presents an immunodominant peptide from the RSV G protein to CD4 T cells. Virology 326: 220-230.
24. Wang QM, Sun SH, Hu ZL, Zhou FJ, Yin M, et al. (2004) Epitope DNA vaccines against tuberculosis: spacers and ubiquitin modulates cellular immune responses elicited by epitope DNA vaccine. Scandinavian Journal of Immunology 60: 219-225.
25. Gao DY, Jin GD, Yao BL, Zhang DH, Gu LL, et al. (2010) Characterization of the specific CD4+ T cell response against the F protein during chronic hepatitis C virus infection. PLoS One 5 (12): e14237.
26. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, et al. (2008) Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 82 (1): 546-54.
27. Wang XF, Cohen WM, Castelli FA, Almunia C, Lethe B, et al. (2007) Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol Immunother 56: 807-818.
28. Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, et al. (2005) One NYESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol 174: 1751-1759.
29. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, et al. (1997) HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185: 2043-2051.
30. Lone YC, Pajot A, Lemonnier F, (2006) Transgenic mice and use there of as an experimental model. Patent publication, WO 2006/092515 A1.
31. Michel ML, Davis HL, Schleef M, Mancini M, Tiollais P, et al. (1995) DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl.Acad Sci USA 92: 5307-5311.
32. Schultz ES, Lethe B, Cambiaso CL, Van Snick J, Chaux P, et al. (2000) A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res 60 (22): 6272-6275.
33. Cosgrove D, Gray D, Dierich A, Kaufman J, Lemeur M, et al. (1991) Mice lacking MHC class II molecules. Cell 66: 1051-1066.
34. Law YM, Yeung RS, Mamalaki C, Kioussis D, Mak TW, et al. (1994) Human CD4 restores normal T cell development and function in mice deficient in murine CD4. J Exp Med 179 (4): 1233-42.
35. Maini MK, Boni C, Ogg GS, King AS, Reignat S, et al. (1999) Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 117: 1386-1396.
36. Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, et al. (1993) HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 150: 4659-4671.
37. Schirmbeck R, Wild J, Reimann J, (1998) Similar as well as distinct MHC class I-binding peptides are generated by exogenousand endogenous processing of hepatitis B virus surface antigen. Eur J Immunol 28: 4149-4161.
38. Busson M, Castelli FA, Wang XF, Cohen WM, Charron D, et al. (2006) Prediction of CD4+ T cell epitopes restricted to HLA-DP4 molecules. J Immunol Methods 20; 317 (1-2): 144-51.
39. Sidney J, Steen A, Moore C, Ngo S, Chung J, et al. (2010) Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity. J Immunol 184: 2492-2503.
40. Gaschet J, Lim A, Liem L, Vivien R, Hallet MM, et al. (1996) Acute graft versus host disease due to T lymphocytes recognizing a single HLA-DPB1*0501 mismatch. J Clin Invest 98: 100-107.
41. Pajot A, Schnuriger A, Moris A, Rodallec A, Ojcius D, et al. (2007) The Th1 immune response against HIV-1 Gag p24-derived peptides in mice expressing HLA-A02.01 and HLA-DR1. European Journal of Immunology 37: 2635-2644.
42. Deng Q, Mancini-Bourgine M, Zhang X, Cumont MC, Zhu R, et al. (2009) Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models. Hepatology 50: 1380-91.
43. Gelder C, Davenport M, Barnardo M, Bourne T, Lamb J, et al. (1998) Six unrelated HLA-DR-matched adults recognize identical CD4+ T cell epitopes from influenza A haemagglutinin that are not simply peptides with high HLA-DR binding affinities. Int Immunol 10: 211.
44. Tussey LG, Rowland-Jones S, Zheng TS, Androlewicz MJ, Cresswell P, et al. (1995) Different MHC class I alleles compete for presentation of overlapping viral epitopes. Immunity 3: 65-77.
45. Lacey SF, Villacres MC, La Rosa C, Wang ZD, Longmate J, et al. (2003) Relative dominance of HLA-B*07 restricted CD8+ T lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 64: 440-452.
46. François V, Ottaviani S, Renkvist N, Stockis J, Schuler G, et al. (2009) The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res 69 (10): 4335-45.